Psychometric performance of tools to measure internalized drug use stigma among people who use drugs and people on medication-assisted treatment in Dar es Salaam, Tanzania.

Journal: Drug and alcohol dependence

Volume: 264

Issue: 

Year of Publication: 

Affiliated Institutions:  The Ohio State University, College of Public Health, Department of Epidemiology,  Neil Avenue, Columbus, OH , United States; RTI International, Social, Statistical and Environmental Sciences,  East Cornwallis Drive, Durham, NC , United States. Electronic address: endres-dighe.@buckeyemail.osu.edu. Muhimbili University of Health and Allied Sciences, School of Public Health and Social Sciences, Department of Community Health, P.O. Box , Dar es Salaam, Tanzania. RTI International, Social, Statistical and Environmental Sciences,  East Cornwallis Drive, Durham, NC , United States. Muhimbili University of Health and Allied Sciences, Department of Psychiatry and Mental Health, P.O. Box , Dar es Salaam, Tanzania; Muhimbili National Hospital, Department of Psychiatry and Mental Health, P.O. Box , Dar es Salaam, Tanzania. Muhimbili National Hospital, Department of Psychiatry and Mental Health, P.O. Box , Dar es Salaam, Tanzania.

Abstract summary 

People who use drugs (PWUD) and people who use medication-assisted treatment (MAT) to treat opioid use disorder face severe stigma. Stigma may manifest in delayed health-seeking behaviors, which adversely affects health and increases disease risk. Few validated measures assess internalized drug use stigma or MAT disclosure concerns in sub-Saharan Africa. This study examines the performance of internalized drug use stigma scales and characterizes the prevalence of these stigmas among PWUD and people who use MAT in Dar es Salaam, Tanzania.We conducted a cross-sectional survey among 250 PWUD and 251 MAT clinic clients. Internalized drug use and MAT disclosure concerns were measured using scales adapted to the Tanzanian context. We conducted exploratory factor analysis to identify latent constructs and evaluate reliability of the scales. We then used confirmatory factor analysis to assess construct validity and reliability.The six-item internalized drug use stigma scale (IDUSS) was unidimensional, reflected acceptable goodness-of-fit, and acceptable reliability (Cronbach's α = 0.79). The eight-item internalized drug use stigma scale for people using MAT (IDUSS-MAT) was bidimensional. Allowing error terms of related items to covary improved goodness-of-fit. The IDUSS-MAT demonstrated acceptable reliability (Cronbach's α = 0.79). Among PWUD and MAT clinic clients, higher levels of stigma were associated with increased depression and reduced social support and quality of life.Both the IDUSS and IDUSS-MAT demonstrated good construct validity and acceptable reliability. These validated scales provide the foundation for collecting data to inform the development of stigma reduction interventions in Tanzania and among similar Sub-Saharan populations of PWUD and the tools needed to assess those interventions.

Authors & Co-authors:  Endres-Dighe Stacy M SM Mlunde Linda B LB Oga Emmanuel E Mbwambo Jessie K JK Shomari Zawadi Z Mkufya Judith J Nguma Elizabeth E Teemba Lucy C LC Saalim Khalida K Nyblade Laura L

Study Outcome 

Source Link: Visit source

Statistics
Citations : 
Authors :  10
Identifiers
Doi : 10.1016/j.drugalcdep.2024.112469
SSN : 1879-0046
Study Population
Male,Female
Mesh Terms
Other Terms
Illicit drug use;Medication-assisted treatment;Stigma;Substance use disorder;Tanzania
Study Design
Cross Sectional Study,Exploratory Study
Study Approach
Country of Study
Tanzania
Publication Country
Ireland